Holen Sie sich die Stockscreener-App
7.33
4.42%
0.31
Handel nachbörslich:
7.33
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$7.02
Offen:
$7.06
24-Stunden-Volumen:
913.02K
Relative Volume:
0.74
Marktkapitalisierung:
$683.26M
Einnahmen:
$823.60M
Nettoeinkommen (Verlust:
$-116.00M
KGV:
-5.6385
EPS:
-1.3
Netto-Cashflow:
$-107.30M
1W Leistung:
-3.55%
1M Leistung:
-10.39%
6M Leistung:
+50.20%
1J Leistung:
-54.84%
1-Tages-Spanne:
$7.02
$7.349
1-Wochen-Bereich:
$6.925
$7.72
52-Wochen-Spanne:
$3.76
$16.83
Myriad Genetics Inc Stock (MYGN) Company Profile
Firmenname
Myriad Genetics Inc
Sektor
Branche
Telefon
801-584-3600
Adresse
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Vergleichen Sie MYGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
7.33 | 654.36M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
580.45 | 218.05B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
228.46 | 160.05B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
725.93 | 58.51B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
149.26 | 42.12B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
227.24 | 38.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-10 | Eingeleitet | UBS | Neutral |
| 2024-12-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Underperform |
| 2024-05-08 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Underweight |
| 2023-05-23 | Hochstufung | Goldman | Sell → Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Eingeleitet | Stephens | Equal-Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Sell |
| 2019-09-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Herabstufung | Needham | Strong Buy → Hold |
| 2019-07-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-03-12 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
| 2018-11-30 | Hochstufung | Goldman | Sell → Neutral |
| 2018-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Eingeleitet | Goldman | Sell |
| 2018-01-22 | Bestätigt | Barclays | Equal Weight |
| 2018-01-05 | Eingeleitet | BTIG Research | Buy |
| 2017-10-02 | Fortgesetzt | Leerink Partners | Mkt Perform |
| 2017-08-09 | Bestätigt | Barclays | Equal Weight |
| 2017-02-08 | Hochstufung | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Sell |
| 2016-10-10 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
Alle ansehen
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
Upcoming Virtual Meeting on December 11 Hosted by Craig-Hallum f - GuruFocus
Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report? - Yahoo Finance
4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial - GlobeNewswire Inc.
1 Healthcare Stock with Promising Prospects and 2 We Question - Markets Financial Content
How Myriad Genetics Inc. stock benefits from strong dollarTrade Risk Assessment & Low Drawdown Investment Ideas - Newser
Why Myriad Genetics Inc. stock appeals to analystsJuly 2025 Retail & Smart Allocation Stock Tips - Newser
Can Myriad Genetics Inc. stock continue upward trendDip Buying & High Accuracy Swing Entry Alerts - Newser
Why Myriad Genetics (MYGN) Stock Is Trading Lower Today - Finviz
How Recent Developments Are Shaping the Myriad Genetics Investment Story - Yahoo Finance
UBS Initiates Coverage of Myriad Genetics (MYGN) with Neutral Recommendation - MSN
Will Myriad Genetics Inc. stock return to pre crisis levelsJuly 2025 Outlook & Breakout Confirmation Trade Signals - BỘ NỘI VỤ
Will Myriad Genetics Inc. stock attract more institutional investorsPortfolio Growth Summary & Real-Time Buy Signal Notifications - BỘ NỘI VỤ
Myriad Genetics, Inc. (MYGN) Stock Forecasts - Yahoo Finance
How Myriad Genetics achieved fast, accurate, and cost-efficient document processing using the AWS open-source Generative AI Intelligent Document Processing Accelerator - Amazon Web Services (AWS)
Earnings Recap: Can Myriad Genetics Inc. stock double in next 5 yearsTake Profit & Free Safe Entry Trade Signal Reports - BỘ NỘI VỤ
Myriad Genetics, Neogen, ICU Medical, HCA Healthcare, and Universal Health Services Stocks Trade Up, What You Need To Know - MSN
Clairity, Myriad Genetics, MagView partner on breast cancer risk tools By Investing.com - Investing.com Nigeria
Myriad Genetics partners to use AI to measure breast cancer risk - Seeking Alpha
Clairity, Myriad Genetics, MagView partner on breast cancer risk tools - Investing.com
Clairity, Myriad Genetics, and MagView Collaborate to Enhance Breast Cancer Risk Assessment Tool - Quiver Quantitative
Clairity, Myriad Genetics, Inc. and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health - MarketScreener
Myriad Genetics (NASDAQ: MYGN), Clairity and MagView launch AI breast risk platform - Stock Titan
Myriad Genetics joins Forbes list of America's dream employers for 2026 - Traders Union
Myriad Genetics Inc Stock Analysis and ForecastSmall Cap Stock Opportunities & Low Entry Cost Capital - earlytimes.in
Myriad Genetics Q3 2025 Earnings Preview - MSN
Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know - Yahoo Finance
Can Myriad Genetics Inc. stock sustain market leadershipMarket Activity Report & Real-Time Volume Spike Alerts - newser.com
Is Myriad Genetics Inc. (MYD) stock nearing a technical breakout2025 Key Highlights & Detailed Earnings Play Strategies - newser.com
Will Myriad Genetics Inc. stock benefit from sector rotationJuly 2025 Technicals & Entry Point Strategy Guides - newser.com
Why analysts upgrade Myriad Genetics Inc. stockJuly 2025 Big Picture & Technical Pattern Recognition Alerts - newser.com
Is Myriad Genetics Inc. (MYD) stock a buy on weaknessEarnings Growth Report & High Accuracy Swing Trade Signals - newser.com
Is Myriad Genetics Inc. (MYD) stock attractive for growth fundsMarket Activity Report & Growth Oriented Trade Recommendations - newser.com
How to use a screener to detect Myriad Genetics Inc. breakoutsPortfolio Value Summary & Stepwise Trade Execution Plans - newser.com
How Myriad Genetics Inc. (MYD) stock gains from tech spendingQuarterly Investment Review & Weekly Hot Stock Watchlists - newser.com
Is Myriad Genetics Inc. still worth holding after the dipGold Moves & Low Drawdown Momentum Trade Ideas - newser.com
What’s the recovery path for long term holders of Myriad Genetics Inc.2025 AllTime Highs & Weekly Top Gainers Trade List - newser.com
Will Myriad Genetics Inc. (MYD) stock gain from lower interest ratesBond Market & Real-Time Stock Movement Alerts - newser.com
How Myriad Genetics Inc. (MYD) stock moves in volatile trading sessionsDay Trade & Safe Capital Preservation Plans - newser.com
What earnings revisions data tells us about Myriad Genetics Inc.Market Risk Report & Long-Term Growth Stock Strategies - newser.com
Finanzdaten der Myriad Genetics Inc-Aktie (MYGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.03%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):